#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
Published 3 years ago • 2.2K plays • Length 3:18Download video MP4
Download video MP3
Similar videos
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
8:31
#esmo21 expert video report on her2-positive early breast cancer
-
7:30
#esmo21 expert video report on her2-positive metastatic breast cancer
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
1:41
esmo breast 2021 highlights
-
3:34
neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in os
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
4:11
asco 2020: pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast c...
-
3:05
esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study
-
7:36
esmo 2020 expert video report on atezolizumab in upfront treatment of tnbc
-
10:14
asco: pembrolizumab plus chemotherapy for advanced triple-negative breast cancer
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
2:51
impassion130: design and preliminary efficacy
-
0:41
the importance of brca-1 testing in triple negative breast cancer
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
3:37
tnbc: immunotherapy in the neoadjuvant setting